

Index

Please note: page numbers in **bold type** indicate figures or tables, page numbers in *italic type* indicate definitions

- abdominal dyspareunia, 6
 - vs vaginal, 113
 - abnormalities, recognising, 11–12
 - acanthosis nigricans, *vi*, 94
 - acne, 32, 100
 - acute infective vulvovaginitis, children, 136–7
 - allergic contact dermatitis, most common cause, 19
 - alopecia areata, *vi*
 - amalgam fillings, associated with oral lichen planus, 59
 - ambiguous genitalia, 140
 - amitriptyline, allergic contact dermatitis and, 19
 - amoebiasis, *vi*
 - Amolin® cream, 27
 - anatomy of the vagina, 5
 - anatomy of the vulva, 3–5
 - angiokeratoma, *vi*, **95**, 95–6
 - antibiotics
 - allergic contact dermatitis and, 19
 - as potential trigger of symptoms, 78
 - and relapse of candidiasis, 32
 - antifungal treatments
 - allergic contact dermatitis and, 19
 - candidiasis management, 46
 - diabetes-associated candidiasis, 33
 - diagnosis and treatment, 31
 - ERT-associated candidiasis, 33
 - for diagnosis and treatment of superinfection, 23
 - frequent use of and potential false negative cultures, 29
 - interaction with other drugs, 31, 32
 - lack of response in oestrogen hypersensitivity vulvitis, 33
 - myths about oestrogen and, 148
 - myths about thrush and, 147
 - oral, risks of long-term use, 148
 - potential for irritation, 19, 130, 140
 - potential interaction with other drugs, 31
 - psoriasis with co-existent candidiasis, 27
 - rhabdomyolysis as result of interaction with statins, 31
 - seborrhoeic dermatitis and, 18
 - side effects, 31
 - for superinfection in dermatitis, 23
 - tinea management, 28
 - vulval disease in children and, 129, 140
- anxiety
 - dyspareunia as response to, 114
 - often caused by genital conditions, 152
 - apareunia, *vi*
 - aphthae, *vi*
 - aphthous ulceration, 63–5
 - investigation/diagnosis, 65
 - management, 65
 - presentation/symptoms, 64
 - see also* non-sexually acquired genital ulceration (NSAGU); ulcerative conditions.
 - aphthous ulcers, **64**
 - asthma, 7, 16–17, 32
 - atopic dermatitis, 16, 17, **18**
 - atopy, *vi*, 16–19
 - atrophic vulvovaginitis, 115, 151
 - cause of, 115
 - management, 115
 - presentation/symptoms, 113, 115
- atrophy
 - lichen sclerosus and, 38, 39–40, 42, 45–6
 - children, 41, 47
 - menopausal, topical oestrogen and, 46, 47
 - tears or striae as evidence of, 15
 - topical corticosteroid treatment and, 45, 47, 52
 - autoimmune thyroiditis, *vi*
 - azole antifungal creams, allergic contact dermatitis and, 19
- basal cell carcinoma, 52
 - Behçet's disease, 66–7
 - benign familial pemphigus (Hailey-Hailey disease), 68–9
 - benign lesions, 82
 - benign vulval neoplasia, 92–3
 - benzocaine, allergic contact dermatitis and, 19
 - Bepanthen® ointment, 27
 - bicycle riding, potential for causing tears and splits, 74
- biopsy
 - Behçet's disease, 67
 - bleeding risk with inflammation, 79
 - bullous pemphigoid, 68
 - candidiasis, 30
 - Crohn's vulvitis, 66
 - DIV, 62–3
 - dyspareunia, 126
 - erythema multiforme, 71
 - Extramammary Paget's disease, 34, 105
 - genital warts, 85
 - hidradenitis suppurativa, 101
 - HSV, 72

Index

- biopsy (cont.)
 importance of for effective diagnosis, 103–4
 invasive squamous cell carcinoma,
 distinguishing VIN from, 53
 lichen planus, 59, 63, 79
 lichen sclerosus, 37, 41, 42
 children, 41
 differentiating
 lichenification from, 50
 myths about, 151
 naevi, 96
 neoplasia, 103
 papillomatosis, 91
 pemphigus, 68
 persistent vaginitis and, 79
 persistent vulval ulcer, 73
 the procedure, 154–5
 psoriasis, 25
 sebaceous adenitis, 103
 seborrhoeic keratoses, 89
 situations requiring, 12
 tinea, 28
 VIN
 distinguishing from
 invasive squamous cell carcinoma, 53
 suspected, 55, 104
 vitiligo, 51
 vulval pain, 126
- birthmarks, 128
 haemangiomas of
 infancy, 135
 pigmented naevi, 136
- bladder dysfunction, vulval pain and, 119
- bleb, *vi*
- boils, folliculitis and, 98–9
- boric acid, 32
- Bowen's disease, 53, 103
- bullous conditions, 57
 autoimmune bullous disease,
 67 *see also* bullous pemphigoid;
 pemphigus.
 Hailey-Hailey disease
 (benign familial pemphigus), 68–9
see also erythema multiforme (Stevens-Johnson Syndrome);
 fixed drug eruption.
- bullous pemphigoid, 67–8, 113,
 144, 146
- calcineurin inhibitors, 24, 27
- calcipotriol, 26, 51, 97, 133
- Campbell de Morgan spots, *vi*
- cancer, 42
 genital mucosal erosions
 caused by
 immunotherapy drugs
 for, 70
 HPV virus and, 52
 lichen sclerosus as risk factor
 for, 42
 reassuring the patient, 153
 reducing risk in lichen
 sclerosus patients, 42,
 44–5, 46
 as risk of non-compliance
 with treatment
 regimen, 156
 skin cancers, 52
see also malignancy; vulval
 cancer; *and specific*
cancers.
- Candida*, 12, 29, 31
- Candida albicans*, 22–3, 29,
 31, 45
- Candida glabrata*, 29, 30–1, 32
- candidiasis, *vi*
 antibiotics and relapse of, 32
 anti-candida diet, 148
 antifungal treatments for, 31
 definition, *vi*
 not excluded by vaginal
 culture, 35
 factors associated with
 increased tendency
 to, 31
 myths about thrush and, 147
 potential genetic basis, 31
 potential triggers, 78
 relationship with oestrogen,
 7, 32–3, 128–9, 140, 147
 therapy pitfalls, 35
see also chronic vulvovaginal
 candidiasis.
- cellulitis, *vi*
- chancroid, *vi*
- child sexual abuse
 chronic pelvic pain and,
 123
 genital warts and, 83
 naevi mistaken for leading
 to queries of, 136
 and vulval disease, 143–4
- children
 acute infective
 vulvovaginitis, 136–7
- anatomical abnormalities
 fusion of the labia,
 140–1
 pyramidal perineal
 protrusion, 141
- birthmarks
 haemangiomas of
 infancy, 135
 pigmented naevi, 136
- dermatitis, 129
 common causes, 129
 examination, 130
 investigation/
 diagnosis, 130
 management, 130–1
 presentation/
 symptoms, 130
 specific treatment, 131
- genital herpes, 139
- genital warts, 138–9
- hygiene and vulval
 disease, 129
- labia minora
 fusion of, 140–1
 size and labial asymmetry,
 141–2
- lichen sclerosus, 133
 adolescence and, 134
 carcinoma risk if left
 untreated, 135
 case study, 133
 emotional issues, 134
 importance of careful
 follow-up, 149
 management, 47–8, 134–5
 myths about, 149
 presentation/symptoms,
 40–1, 133–4
 referral to a dermatologist
 recommended, 135
- molluscum
 contagiosum, 138
- pinworm infestation, 138
- psoriasis
 case study, 131–2
 diagnosing, 132
 management, 132–3
 presentation/
 symptoms, 132
- psychological aspects of
 vulval problems, 142
- tinea, 140
- vulval disease in, 128–9
 and sexual abuse, 143–4
- chronic thrush,
 management, 148

- chronic vulvovaginal
 candidiasis, 6, 33
 aetiology, 29
 case study, 28
 diabetes and, 33
 history *vs* swab, 35
 oestrogen replacement
 therapy-associated, 33
 in pregnancy, 32
 presentation/diagnosis, 16,
 29–31, 35
 recovery time, 32
 similarity to oestrogen
 hypersensitivity vulvitis,
 33
 see also candidiasis.
- Cidofovir, 86
- clinical presentation, of
 patients with chronic
 vulval symptoms, 6, 13
- clitoral hyperaesthesia, 39
- clitoral phimosis, lichen planus
 in children and, 47, 133–4
- clitoris, hair tourniquet, 141
- clobetasol propionate, 43–4, 45
- coeliac disease, 8
- comedones, *vi*
- compliance optimisation, tips
 for, 156
- condoms
 genital warts and, 83
 irritant potential, 20, 150–1
 protection from allergic
 reaction to semen, 20
- constipation, 133
- dermatitis and, 129, 131
- dyspareunia and, 116
- lichen sclerosis and, 41
- pelvic floor impact, 8
- corticosteroid dermatitis (peri-
 orificial dermatitis),
 16–17, 20–1, 35, 45, 52
- corticosteroid phobia, 14, 23–4,
 149, 151
- corticosteroids, topical, 14, *see*
 topical
 corticosteroids (TCS).
- cosmetic genital procedures,
 10, 142, 152
- counselling, referral for, 157
- crisaborole, 24
- Crohn's vulvitis, 65–6, 96
 bilateral labial oedema, **66**
 presentation/symptoms, 65
 referral recommended, 66
 cytokines, *vi*
- dermatitis, 16–17
 allergic contact dermatitis,
 19–20
 identification of possible
 allergens, 23
 atopic dermatitis, 16, 17, **18**
 in children, 129–31
 common irritants, 22
 corticosteroid-induced
 (periorificial
 dermatitis), 16–17,
 20–1, 35, 45, 52
 diagnosis, 17
 differential diagnosis of
 lichen sclerosis, 42
 dyspareunia
 management, 24
 endogenous dermatitis, 16
 see also eczema.
 environmental
 modification, 21–2
 exogenous dermatitis, 16
 histological appearances, 16
 irritant contact dermatitis,
 18–19
 management, 21–4
 presentation, 16–17
 seborrhoeic dermatitis, 18
 superinfection diagnosis and
 treatment, 22–3
 topical corticosteroids
 alternatives, 24
 use of, 14, 23–4
 see also eczema.
- dermoscopy, *vi*, 89, 136
- desquamation, *vi*
- desquamative inflammatory
 vulvovaginitis (DIV)
 investigation/
 diagnosis, 62–3
 management, 63
 presentation/symptoms, 62
- diagnosis of vulval conditions,
 difficulty, reasons
 for, 1–2
- diarrhoea, 8, 31, 129
- discharge
 as cause of patient
 distress, 79
- chronic vulvovaginal
 candidiasis and, 29, 78
- DIV and, 62, 63, 78
- surface desquamation
 mistaken for, 79
- types of, 78
- vaginitis and, 76
- dissecting cellulitis of the
 scalp, 100
- Dowling–Degos disease, *vi*, 95
- dysfunctional voiding, as
 potential irritant, 116,
 129, 131
- dyspareunia, *vi*, 6–7
 abdominal, 6
 common in lichen
 sclerosis, 39
 in DIV, 63
 idiopathic, 124–5
 in lichen planus, 58
 vaginal, 6
 vs abdominal, 113
 checking for rash or
 lesions, 117
 complete systems
 review, 116
 diagnosis, 117
 experience of sexual abuse
 and, 123–4
 lesional (nociceptive
 pain), 114
 location of the pain, 118
 non-lesional (non-
 nociceptive pain), 115
 vulval dermatitis-
 associated, 21
- dysuria, 41, 133
- eczema, 16
 and proneness to herpetic
 infection, 139, 143
- psoriasis in children
 mistaken for, 132
- relationship with
 Staphylococcal
 folliculitis, 137
- emotional stress, dyspareunia
 as response to, 114
- endometriosis, 112
- environmental modification
 benefits of, 152
- dermatitis, 21–2
- psoriasis management, 132
- epidermal naevi, 96–7, 135,
 136
- Epstein-Barr, 64
- erythema, *vi*, 11
 bladder dysfunction and, 110
- chronic vulvovaginal
 candidiasis and, 29
- dermatitis in children
 and, 130
- lichen planus and, 59

Index

- erythema (cont.)
 as side effect of topical corticosteroid treatment, 45, 119
 vaginitis and, 76, 78
 erythema multiforme (Stevens-Johnson Syndrome), 70–1
 management, 71
 presentation/symptoms, 71
 exogenous dermatitis, 16
 Extramammary Paget's disease, 34, 81, 103, 106
 biopsy to rule out, 35
 diagnosis, 105
 differential diagnosis of lichen sclerosus, 42
 often mistaken for dermatitis, 54
 presentation/symptoms, 16, 52, 105
 treatment, 105
- faecal incontinence, 8, 126, 153
 dermatitis in children and, 130
 female genital mutilation, 10
 feminine hygiene products, as cause of irritant contact dermatitis, 19
 Fenton's procedure, 125
 fexofenadine hydrochloride, 31
 fibromas (skin tags), 90
 fissuring, traumatic, 73–4
 fixed drug eruption, 69–70, 78–9, 113, 146
 aetiology, 69
 drug classes strongly associated with, 69
 investigation/diagnosis, 70
 management, 70
 other ulcerative vulval drug eruptions, 70
 presentation/symptoms, 70
 fluconazole, 23, 28–9, 31–3, 100, 148
 fluorouracil, 86
 folliculitis, *vi*
 Staphylococcal folliculitis, in children, 137
 waxing as potential cause of, 19
 fomites, *vi*
 foreign bodies, as cause of vulval disease in children, 141
- formication, 6
 foscarnet, association with genital ulceration, 70
 fourchette, *vi*
 Fox–Fordyce disease, *vii*, 91–2
 fusion of the labia, 128
 in children, 140–1
- genital herpes, 112
 acute, 74
 in children, 139
 implications, 72
 potential recurrence, 72
 virus responsible for, 72
- genital warts
 aetiology, 83
 in children, 83, 138–9
 confused with pyramidal perineal protrusion, 141
 differential diagnosis
 HPV, 85
 lichen sclerosus, 42
 follow up, 87
 HPV and, 50, 82
 and HPV vaccination, 85
 management, 85–7
 non-infective lesions that may be confused with, 136
 in pregnancy, 86–7
 psychological issues, 87
 sex partners, treatment of, 87
 treatments, self-administered, 86
 typical presentation, 83–4
 uVIN masquerading as, case study, 103–4
 vulval mollusca, differentiating, 138
- gingivitis, in oral lichen planus, 58
 graft versus host disease, and lichen planus, 61
 Group A Streptococcus, 96, 131, 147
 Group B Streptococcus, 23, 62
 gynaecology, myths about the role of, 150–1
- haemangiomas of infancy, 135
 haemorrhoids, 8
 Hailey–Hailey disease (benign familial pemphigus), 68–9
 hair removal products, vulval dermatitis and, 19
- hair tourniquet, on the clitoris, 141
 hamartoma, *vii*
 Hashimoto's thyroiditis, association with lichen sclerosus, 38
 hay fever, 7, 16–17
 Hepatitis B and C, relationship with lichen planus, 58
 herpes, differential diagnosis, 139
 herpes simplex, 12, 72
 conditions precipitated by, 8, 71
 investigation/diagnosis, 72
 management, 73
 presentation/symptoms, 72
see also genital herpes.
- hidradenitis suppurativa, *vii*, 28, 100
 aetiology, 100
 differential diagnosis, 101
 investigation/diagnosis, 100
 management, 101–3
 presentation/symptoms, 100
 surgery, 102–3
- history taking
 dermatological history, 7
 environmental history ('secret women's business'), 9
 gastroenterological history, 8
 gynaecological history, 7–8
 musculoskeletal history, 8
 patient beliefs, 9–10
 psychological history, 9
 summary of, 10
 urological history, 8
- hormone replacement therapy (HRT), DIV and, 63
 human papilloma virus (HPV), 104
 association with cancer of the cervix, 52
 Cidofovir treatment, 86
 genital warts
 caused by HPV, 82
 differential diagnosis, 85
 infection, 50
 management, 85–7
 in pregnancy, 87
 vaccination, 85
 vertical transmission at birth, 83
 VIN and, 52, 54

- genotypes most often associated, 104
- hymenal remnants, mistaken for abnormal lesions, 82
- hyperalgesia, *vii*, 115, 155
- hypersensitivity reactions, 16
- hypopigmentation, post-inflammatory, 52
- ‘ideal vulva’, myths about, 152
- imidazole antifungal creams, potential irritant reaction, 19
- imperforate hymen, 140
- incontinence, asking about, 153
- inflammatory dermatoses, 16
- ingenol mebutate, 86
- inguinal, *vii*
- intercourse, 6 *see* sexual intercourse.
- International Society for the Study of Vulvar Disease (ISSVD), 107, 142
- intertriginous, *vii*
- investigations, most commonly performed, 12–13
- irritable bowel, 112
- irritants, potential, 5
- itchy rashes, 16
 - examples of vulval skin problems presenting as, 16
 - see also* red vulval rashes.
- itraconazole, 28, 31, 32, 100, 148
- Koebner phenomenon, *vii*, 40
- labia minora
 - fusion, in children, 140–1
 - variation in size and asymmetry, 11, 141–2
- labiaplasty, 10, 82, 142
- laser treatment, 46
- latex, as potential cause of irritant reaction, 20, 23, 131
- leishmaniasis, *vii*
- leukoplakia, 37, *see* white patches/lesions.
- lichen planus, 11, 13, 58
 - aetiology, 58–9
 - diagnostic clues, 10
 - differential diagnosis, 60–1
 - differentiating from lichen sclerosis, 61
- examination, 59
- follow-up, 60
- graft versus host disease and, 61
- hallmark, 59
- investigation/diagnosis, 59
- management, 60
- presentation/symptoms, 58
- resistance to treatment, 59
- specialist referral
 - recommended, 60
- surgical treatment, 60
- TCS use, 14
- lichen sclerosis, 6, 11, 38, 114
 - aetiology, 38
 - association with
 - autoimmune disease, 38
 - association with vitiligo, 38, 51–2
 - case study, 37
 - children and adolescents, 133–5
 - diagnosis, 41
 - management, 47–8
 - myths about, 149
 - presentation/symptoms, 40–1, 133–4
 - sexual abuse concerns, 48
 - complication risks, 38
 - diagnosis
 - children, 41
 - differential, 42
 - differentiating lichen planus from, 61
 - differentiating
 - lichenification from, 50
 - differentiating vitiligo from, 50–1
 - distribution, 38, 40
 - epidemiology, 38
 - genetic factors, 39
 - herpes and, 72
 - investigation/
 - diagnosis, 41–2
 - loss in pigmentation after treatment, 52
 - maintenance
 - treatment, 44–6
 - malignancy
 - after treatment, 42–3
 - prevention of, 43
 - risk of, 42, 46–7
 - management, 43–9
 - children and adolescents, 47–8
 - mean age of onset, 38
- with minimal
 - lichenification, 38
- myths about, 149
- perineal fissures, 74
- presentation/symptoms, 39–40
 - in children, 40–1, 133–4
- prevalence, 38
- resumption of normal sexual activity, 48–9
- risk factor for cancer, 42
- serum auto-antibodies and, 38
- with severe anterior labial fusion, 41
- side effects of treatment, 46
- surgical therapy, 48
- TCS and, 150
- testing for associated diseases, 39
- topical therapy
 - corticosteroids, 14, 43–4, 150
 - immunosuppressive agents, 46–7
 - VIN and, 52, 54–5, 104
- lichenification, *vii*, 11, 37, 42, 49
 - conditions prone to, 49
 - in dermatitis, 17, 49–50
 - differentiating from lichen sclerosis, 50
 - presentation, 49
 - in psoriasis, 25–6
 - and topical corticosteroid use, 23
- Lipschutz ulcer, 64
- liquor picis carbonis (LPC), 26
- liver, risks of antifungal drugs to, 148
- lubricants, 20
 - as potential irritant, 78
- lumps and lesions, 89
 - acanthosis nigricans, 94
 - angiokeratomas, 95–6
 - benign lesions, 82
 - benign vulval neoplasia, 92–3
- Dowling–Degos disease, *vi*, 95
- epidermal naevi, 96–7
- Extramammary Paget’s disease, *see* Extramammary Paget’s disease.
- folliculitis, 98–9

Index

- lumps and lesions (cont.)
 Fox-Fordyce disease, 91–2
 hidradenitis suppurativa, *vii*
 see hidradenitis suppurativa.
 lymphangiectases, 96
 malignant lesions, 82
 melanocytic naevi, 92
 melanoma, 106
 melanosis vulvae, 93
 molluscum
 contagiosum, 87–8
 neoplasia, 103
 normal variants, 81–2
 papillomatosis, 90–1
 pyramidal perineal
 protrusion, 141
 sebaceous adenitis, 103
 sebaceous hyperplasia, 91
 seborrhoeic keratoses, 89
 skin tags (fibromas), 90
 syringomas, 92
 tinea, 99–100
 vulval
 hyperpigmentation, 94
 warts and other lesions, 82–7
 see also genital warts; human
 papilloma virus (HPV);
 vulval intraepithelial
 neoplasia (VIN).
- lymphangiectases, 96
 lymphogranuloma venereum,
 vii, 73
- maceration, *vii*
 macule, *vii*
 Malassezia yeast, as trigger for
 seborrhoeic
 dermatitis, 18
 malignancy, 81, 103
 acanthosis nigricans and, 94
 after lichen sclerosus
 treatment, 42–3
 naevi and, 136
 prevention of in cases of
 lichen sclerosus, 43
 risk of with lichen sclerosus,
 42, 46–7
 ruling out with biopsy, 46
 signs of, 13
 VIN and, 53
 malignant lesions, 82
 malignant melanoma,
 percentage of all vulval
 cancers, 42
 marsupialisation, *vii*, 102
- melanocytic naevi, 92
 melanoma, 52, 54, 95, 106
 birthmarks and, 135
 in children, 136
 confusion of seborrhoeic
 keratoses with, 89
 differentiating from
 melanosis vulvae, 93
 melanosis vulvae, 93
 menopausal atrophy, 38
 methotrexate, association with
 genital ulceration, 70
 methylisothiazolinone, allergic
 contact dermatitis
 and, 20
 molluscum contagiosum,
 vii, 87–8
 in children, 138
 mometasone furoate, 43–4,
 131
 morphoea, *vii*
 mucosal petechiae, *vii*
Mycoplasma pneumoniae, 71
 myths
 about biopsy, 151
 about lichen sclerosus, 149
 about oestrogen, 148
 about psoriasis, 150
 about the ‘ideal vulva’, 152
 about the role of
 gynaecology, 150–1
 about thrush, 147–8
 about topical corticosteroids,
 149–50
 about vulvodynia, 151
 that vulval symptoms are
 often due to psychiatric
 disease, 151
- naevi, *vii*
 epidermal, 96–7, 135, 136
 melanocytic, 92
 pigmented, 136
 nappies (diapers)
 dermatitis and, 129
 dermatitis in children
 and, 130
 psoriasis and, 132
 Staphylococcal folliculitis
 and, 137
 neoplasia, 103
 nerve supply
 pelvis and genital area,
 109–10
 to the vulva, 110, 120
 neurofibromatosis, *vii*
- non-corticosteroid
 preparations, 26
 non-infective chronic
 vulvovaginitis, 61, *see*
 desquamative
 inflammatory
 vulvovaginitis (DIV).
 non-pigmented seborrhoeic
 keratosis, 42
 non-sexually acquired genital
 ulceration (NSAGU),
 vii, 63
 aetiology, 64
 investigation/diagnosis, 65
 management, 65
 presentation/symptoms, 64
 see also aphthous ulceration;
 ulcerative conditions.
- oestrogen
 myths about, 148
 relationship with
 candidiasis, 7, 32–3,
 128–9, 140, 147
 oestrogen creams, allergic
 contact dermatitis
 and, 19
 oestrogen hypersensitivity
 vulvitis, 33–4
 diagnosis, 34
 presentation/symptoms, 16
 oestrogen replacement
 therapy-associated
 candidiasis, 33
 oestrogen status, importance
 of, 7
- ointments
 application advice, 155
 comparison with creams, 14,
 22, 23, 112, 131, 156
- oral azoles
 diagnostic use, 31, 79
 recommended to avoid
 causing irritation, 23
 oral corticosteroids, treatment
 of lichen planus, 60
 oral prednisone
 Crohn’s vulvitis
 treatment, 66
 lichen planus
 ruling out, 79
 treatment, 60
 pemphigus treatment, 68
 over-the-counter preparations
 dermatitis in children
 and, 130

Index

- importance of asking about
 in history-taking, 70,
 78, 130
 irritant potential, 69
- pain, understanding chronic
 pain, 110–11
 pain management, patient
 referral for, 157
 pain sensation, fibres mediated
 by, 110
 papilloma, *vii*
 papillomatosis, vulval, 90–1
 papules, *vii*
 paracetamol, as potential cause
 of fixed drug eruption,
 69, 70
 patient categorisation, 13
 pearls of wisdom
 asking about faecal and
 urinary
 incontinence, 153
 asking about sexual
 functioning, 152
 asking parents whether
 concerned about sexual
 abuse, 153
 benefits of environmental
 modification, 152
 compliance
 optimisation, 156
 genital conditions always
 cause anxiety, 152
 ointment application,
 showing the patient,
 155
 patient referral
 counselling, 157
 pain management, 157
 pelvic floor
 physiotherapy, 156
 provision of factual and
 accurate
 information, 154
 reassuring the patient
 non-transmissibility, 153
 sexually transmissible
 infections and
 cancer, 153
 stinging medications, 155
 treatment of adolescents, 154
 vulval biopsy, procedure,
 154–5
 pedunculated, *vii*
 pelvic anatomy, components of
 the lower pelvis, 109
- pelvic floor
 anatomy of, 5
 hip joints related to, 109
 patient referral for
 physiotherapy, 156
 structure and function, 109
 pemphigoid, cicatricial, 67
 pemphigus, 67–8
 peri-oral dermatitis
 (corticosteroid-induced
 dermatitis), 17, 20–1,
 35, 45, 52
 pernicious anaemia, *vii*
 persistent vaginitis, 76
 diagnosis
 differential
 diagnosis, 76–7
 examination and, 78–9
 history-taking and,
 77–8
 investigations and
 management, 79
 non-offensive vaginal
 discharge and no other
 symptoms, 79
 specialist referral
 recommended for
 perplexing cases, 79
 personal hygiene
 patients' beliefs, practices
 and rituals, 9
 treatment failure and, 151
 vulval disease in children
 and, 129
 pessaries, as potential
 irritant, 78
 PFAPA syndrome, 64
 physical examination of the
 vulva and vagina, 10–11
 finding abnormalities
 during, 11–12
 speculum examination, 12
 physiological variations of the
 vulva, common, 11
 physiotherapy
 management of non-lesional
 vulval pain, 121–2
 pelvic floor, 156
 pigmentation, common
 variations, 11
 pigmented naevi, 136
 pilonidal sinuses, 100
 pimecrolimus, 24, 27, 46
 pinworm infestation, in
 children, 138
 Plasma Cell vulvitis, 61
- post-inflammatory
 hypopigmentation, 52
 potential irritants, exposure of
 the vulva to, 5
 pregnancy
 candidiasis in, 32
 genital warts in, 86–7
 hidradenitis suppurativa
 and, 102
 HPV in, 87
 prolapse, 112, 121
 pruritus, *vii*
 psoriasis, 24–7
 children, 131–3
 co-existence with lichen
 sclerosus, 42
 diagnosis, 24–6
 history, 24
 management, 26–7
 myths about, 150
 precipitated by Streptococcal
 genital infection, 136
 presentation/symptoms, 16
 TCS use, 14
 psychiatric disease, myths
 that vulval symptoms
 are often due to,
 151
 pubococcygeus muscle
 spasm, 114
 punctum, *vii*
 pyramidal perineal
 protrusion, 141
- red vulval rashes, 26
 oestrogen hypersensitivity
 vulvitis, 33–4
 therapy pitfalls, 34–5
 tinea, 27–8
 see also candidiasis; chronic
 vulvovaginal
 candidiasis; dermatitis;
 Extramammary Paget's
 disease; psoriasis.
- referrals, vulval disease in
 children, when to
 refer, 145
 referrals recommended
 for children with lichen
 sclerosus, 135
 for counselling, 157
 for Crohn's vulvitis, 66
 for lichen planus, 60
 pain management, 157
 pelvic floor
 physiotherapy, 156

Index

- referrals recommended (cont.)
for perplexing cases of
persistent vaginitis, 79
- referred vulval pain
importance of the concept, 1
pelvic floor and, 5
- rhabdomyolysis, as result of
interaction of antifungal
treatments with
statins, 31
- rituximab, association with
genital ulceration, 70
- rugose, *vii*
- sanitary pads, 20
- scarring
cicatricial pemphigoid
and, 67
graft versus host disease
and, 61
lichen sclerosus and, 47–8
in children, 134
diagnosis, 50
non-compliance with
treatment and, 46
not produced by DIV, 61–2
reducing likelihood of,
42, 44–5
risks of surgery for, 103
surgical correction, 60
in untreated lichen
planus, 59
- sebaceous adenitis, *vii*, 103
- sebaceous cysts, 98
- sebaceous hyperplasia, *vii*, 91
- seborrheic dermatitis, 18
- seborrheic keratoses, *vii*, 89
- semen, as potential irritant, 20
- serum auto-antibodies,
association between
lichen sclerosus and the
presence of, 38
- sexual abuse
asking parents whether
concerned about, 153
genital herpes infection in
children and, 72, 139,
143–4
genital warts in children and,
138, 144
and vulval disease in
children, 143
- sexual functioning, asking
about, 152
- sexual intercourse, 6, 82,
108, 151
- dermatitis and, 24
- distaste for caused by
dyspareunia, 48, 119
- fusion of labia minora
and, 40
- graft versus host disease
and, 61
- lesional pain and, 112, 114
- pain with, 6–7 *see also*
dyspareunia.
- post menopausal women, 46
- as potential cause of irritant
reaction, 19
- talking about with
patients, 152
- tears and splits arising from
friction during, 74
- tears during as evidence of
atrophy, 15
- telangiectasia and, 20
- topical corticosteroid use
and, 150
- side effects
amitriptyline, 120
corticosteroids, 20–1
intralesional botulinum
toxin, 126
lichen sclerosus
treatment, 45–6
oral azoles, 31
topical oestrogen, 115
tricyclics, 119
- Sjogren's syndrome, 7
- skin tags (fibromas), 90
- somatoform disorder, 122–4
- speculum examination, 12, 59,
75, 78, 117
- spinal disorders, potential
impact, 109
- spongiosis, *vii*, 16
- spongiotic dermatitis, 16, 26
- sporting activities
dermatitis in children
and, 131
tears and splits arising from
friction during, 74
vulval dermatitis and, 19
- squamous cell carcinoma,
53, 55
Bowen's disease and, 53
metastasising potential,
104
relationship with lichen
sclerosus, 42, 47, 135
see also vulval intraepithelial
neoplasia (VIN).
- squamous cell malignancy,
lifetime risk carried by
lichen sclerosus, 38
- squamous hyperplasia, 50
- staphylococcal folliculitis, in
children, 137
- staphylococcal infection,
hidradenitis
suppurativa and, 100
- Staphylococcus aureus*, 23,
98, 130
- statins, interaction with
antifungals, 31
- stenosed, *vii*
- steroids, safe topical use of on
the vulva, 14
- steroid-sparing agents
Crohn's vulvitis, 66
for treatment of lichen
planus, 60
- streptococcal perianal
dermatitis, 136
- streptococcal throat infections,
and exacerbation of
psoriasis, 24
- streptococcal vulvovaginitis,
136–7
- Streptococcus*
Group A, 96, 131, 147
Group B, 23, 62
Streptococcus pyogenes, 23
- striae, *vii*
- superinfection
in dermatitis, 17, 23
children and, 130
diagnosis and
treatment, 22–3
in Hailey-Hailey disease, 69
as reason for topical
corticosteroid
failure, 43
- Sutton's Ulcer, 64
- swimming
dermatitis and, 129
children, 130–1
molluscum contagiosum
and, 87–8, 138
- symptoms
common, 6
types and meaning of, 6
- syringomas, *viii*, 92
- systemic lupus
erythematosus, 7
- tacrolimus, 24, 27, 46, 51
- tampons, 22, 49, 145, 152

Index

- dysmenorrhea symptoms
 and, 69
 fear of using, 48, 134
 irritant potential, 9
 pain during insertion, 7, 114,
 124, 156
 pain during removal, 112
 retention causing persistent
 vaginitis, 76
 talking about with
 adolescents, 154
 toxic shock and, 9
 tea-tree oil, allergic contact
 dermatitis and, 19
 telangiectasia, *viii*
 thrush, 147
 management of chronic
 thrush, 148
 myths about, 147–8
see also candidiasis.
 tinea, 99, 100
 antifungal medications
 for, 28
 in children, 140
 presentation/symptoms, 16
 topical anaesthetics, allergic
 contact dermatitis
 and, 19
 topical antifungals, vulval
 application, 35
 topical calcineurin inhibitors,
 stinging risk, 27
 topical corticosteroids (TCS)
 and atrophy, 45, 47, 52
 benefits of using antifungal
 creams in addition to, 18
 bullous pemphigoid
 treatment, 68
 dermatitis induced by (peri-
 orificial dermatitis),
 16–17, 20–1, 35, 45, 52
 dermatitis treatment, 23–4
 allergic contact
 dermatitis, 19
 alternatives for, 24
 severe dermatitis in
 children, 131
 erythema as side effect of
 treatment with, 45, 119
 Hailey-Hailey disease
 treatment, 69
 information on selected
 preparations, 15
 lichen planus treatment,
 60, 79
 lichen sclerosis treatment,
 14, 43–4, 150
 children, 134
 as ‘one size fits all’
 treatment, 149
 lichenification and, 23
 long-term use, 35
 myths about, 149–50
 ointments *vs* creams, 23
 patient safety, 14–15
 psoriasis treatment, 26
 children, 132–3
 safe and effective use, 14–15
 superinfection as reason for
 failure, 43
 tinea in children as result of
 treatment with, 140
 use of on the vulva, 14
 vitiligo treatment, 51–2
 topical oestrogen, 35
 topical psoralens, 51
 topical therapies
 allergic reactions, 7
 comparison of ointments
 and creams, 14, 22, 23,
 112, 131, 156
 toxic epidermal necrolysis, 71
 treatment, 71
 transgender patients, 2
 traumatic fissures, 73–4
 treatment failures, potential
 reasons for, 151
 Type IV allergic response, 19
 ulceration, 73
 cicatricial pemphigoid, 67
vs erosion, 57
 erythema multiforme, 71
 in the case of haemangioma
 of infancy, 135
 in VIN, 53–4
 and vulval cancer, 57
 ulcerative conditions
 Behçet’s disease, 66–7
 history-taking, 74
 other infections which may
 cause ulceration, 73
 ulcerative vulval drug
 eruptions, 70
see also aphthous ulceration;
 Crohn’s vulvitis;
 erythema multiforme
 (Stevens-Johnson
 Syndrome); herpes
 simplex; non-sexually
 acquired genital
 ulceration (NSAGU).
 Ulcus Vulvae Acutum, 64
 umbilicated, *viii*
 urinary incontinence
 association with vulval
 disorders, 8
 dermatitis in children
 and, 130
 lichen sclerosis and, 40
 measures to help, 153
 vulval dermatitis and, 18–19
 urinary tract infections
 in children, 128
 fusion of labia and, 140
 ruling out, 130
 vaginal anatomy, 5
 vaginal azoles, prolonged
 use, 34
 vaginal culture, 35
 vaginal dyspareunia, 6 *see*
 dyspareunia, vaginal.
 vaginitis, 76 *see also* persistent
 vaginitis.
 variations of the vulva,
 common, 11
 vesicle, *viii*
 vestibulectomy, 125, 126
 violaceous, *viii*
 vitiligo, *viii*, 50–1, 52
 association with lichen
 sclerosis, 38, 51–2
 presentation, 42
 vulva, anatomy of, 3–5
 vulval cancer, 104
 gynaecology and, 150
 and importance of follow up
 of lichen sclerosis, 46
 malignant melanoma,
 percentage of, 42
 management, 55
 prognosis in the case of
 spread beyond groin
 lymph nodes, 104
 settings occurring in, 54–5
 and ‘squamous
 hyperplasia’, 50
 ulceration and, 57
see also vulval intraepithelial
 neoplasia (VIN).
 vulval conditions
 difficulty of diagnosis,
 reasons for, 1–2
 understanding, 2–3

Index

- vulval disease
 - association with bladder dysfunction, 8
 - in children, 128, 135–6
 - acute infective
 - vulvovaginitis, 136–7
 - adolescent girls, 144–5
 - birthmarks mistaken for, 135–6
 - causes of, **146**
 - dermatitis, 129–31
 - foreign bodies as cause of, 141
 - genital herpes, 139
 - genital warts, 138–9
 - impetigo, 137
 - vs* in adults, 128–9
 - lichen sclerosus, 133–5
 - myths about, 149
 - molluscum
 - contagiosum, 138
 - pinworm, 138
 - psoriasis, 131–3
 - psychological
 - management, 144
 - relationship with
 - hygiene, 129
 - sexual abuse and, 143
 - Staphylococcal
 - folliculitis, 137
 - tinea, 140
 - when to refer, 145
 - emotional significance for
 - patients, 2
- vulval hyperpigmentation, 94
- vulval intraepithelial neoplasia (VIN), 52–3, 103–4
 - colposcopy and, 13
 - differential diagnosis of
 - lichen sclerosus, 42
 - epidemiology, 54–5
 - HPV vaccination and, 85
 - investigation/diagnosis, 55
 - lifetime risk carried by lichen sclerosus, 38
 - management, 55, 104
 - presentation/symptoms, 53–4, 104
 - prognosis, 54
 - resemblance of seborrhoeic
 - keratoses to, 89
 - terminology, 54
 - uVIN masquerading as
 - ‘warts’, case study, 103–4
- vulval melanosis, benign, **93**
- vulval pain
 - and bladder dysfunction, 110
 - case study, 111, 118
 - chronic, 110–11
 - history-taking, 115–16
 - neuro-plasticity and, 112
 - conditions which may
 - cause, 113
 - depressed or obsessive
 - patients, 124
 - diagnosing, 126
 - examination, 117–18
 - lesional pain, 112
 - nerve supply and, 109–10
 - neuropathic, 118–20
 - complementary medicine,
 - counselling and explanation, 120
 - exercise and, 120
 - management, 119–20
 - non-lesional, 112–13
 - characteristics, 113
 - lesional *vs*, 108, 111
 - physiotherapy
 - management, 121–2
 - role of, 121
 - pathophysiology, 108–11
 - physical stress and, 108
 - presentation, 111–13
 - provoked *vs*
 - unprovoked, 107
 - referred pain, 109, 120–2
 - somatoform disorder, 122–4
 - surgical treatment, 125–6
 - terminology and
 - classification, **108**
 - vaginal dyspareunia, 113
 - atrophic
 - vulvovaginitis, 115
 - vulvodynia, 108
 - the term, 107
- vulval symptoms, psychiatric
 - disease myth, 151
- vulvodynia
 - meaning of, 2, 107
 - myths about, 151
- vulvovaginal disorders,
 - frequent association
 - with bladder, menstrual and bowel dysfunction, 6
- vulvovaginitis, *viii*
- warts, epidermal naevi
 - mistaken for, 136
- wet wipes, allergic contact
 - dermatitis and, 20
- white patches/lesions, 37
 - case study, 49
 - lichenified dermatitis (lichen simplex chronicus), 49–50
 - post-inflammatory
 - hypopigmentation, 52
 - vitiligo, 50
 - see also* human papilloma virus (HPV); lichen sclerosus; vulval intraepithelial neoplasia (VIN).
- Wickham’s striae, 58
- zinc and castor oil cream, 27
- Zoon’s vulvitis, 61